Psoriatic arthritis is a chronic autoimmune condition that affects millions of people worldwide. The disease can cause joint pain, stiffness, swelling, and skin symptoms related to psoriasis. For many patients, finding effective treatment options can be challenging, especially when symptoms affect both joints and skin.
A significant advancement has recently been announced in the treatment landscape. The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib), a new oral medication developed by Bristol Myers Squibb, for adults with active psoriatic arthritis. This approval introduces the first selective TYK2 inhibitor for this condition and offers patients a new therapeutic option.
This article explores what Sotyktu is, how it works, key clinical trial results, potential benefits, safety considerations, and what this approval could mean for people living with psoriatic arthritis.
Psoriatic arthritis is a chronic inflammatory disease that affects the joints and skin. It commonly develops in people who already have psoriasis, although it can sometimes appear before skin symptoms develop.
The condition may cause:
Studies suggest that up to 30 percent of individuals with psoriasis eventually develop psoriatic arthritis. If untreated, the disease can progress and lead to permanent joint damage.
Because psoriatic arthritis affects both the immune system and musculoskeletal system, treatment often focuses on reducing inflammation, controlling immune activity, and preventing joint damage.
In March 2026, the U.S. Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. The drug is an oral medication taken once daily.
Sotyktu is notable because it represents the first tyrosine kinase 2 (TYK2) inhibitor approved for this condition. TYK2 is an enzyme involved in immune signaling pathways that drive inflammation in autoimmune diseases.
The approval was based on positive results from two large Phase 3 clinical trials known as POETYK PsA-1 and POETYK PsA-2. These studies evaluated the effectiveness and safety of Sotyktu in adults with active psoriatic arthritis.
Sotyktu works by selectively targeting the TYK2 enzyme, which plays a role in the immune system's inflammatory signaling pathways.
Specifically, the medication affects the activity of several cytokines involved in autoimmune diseases, including:
These signaling molecules are believed to contribute to the development and progression of both psoriasis and psoriatic arthritis.
Unlike some related drugs that inhibit broader Janus kinase (JAK) pathways, Sotyktu was designed to selectively inhibit TYK2. This targeted approach may help reduce inflammatory signaling while minimizing effects on other pathways.
The FDA approval was supported by results from the Phase 3 POETYK PsA clinical trial program. These randomized, double-blind, placebo-controlled studies evaluated Sotyktu in adults with active psoriatic arthritis.
This study included 670 participants who had not previously received biologic disease-modifying antirheumatic drugs.
At Week 16, results showed:
ACR20 refers to a 20 percent improvement in symptoms according to the American College of Rheumatology criteria.
Additional improvements were also observed:
This trial included 624 participants, some of whom had previously received TNF inhibitor treatment.
Results at Week 16 showed:
Other outcomes included:
These findings demonstrated statistically significant improvements in disease activity among patients receiving Sotyktu.
Beyond joint symptom improvements, researchers also evaluated health-related quality of life using the 36-Item Short Form Health Survey (SF-36).
Patients treated with Sotyktu experienced improvements in physical health scores compared with placebo. Improvements were seen across several physical health areas, including:
For patients living with psoriatic arthritis, these improvements can translate into better mobility, reduced pain, and improved daily functioning.
The safety profile of Sotyktu in patients with psoriatic arthritis was generally consistent with previous studies in plaque psoriasis.
The most frequently reported adverse reactions included:
These side effects occurred in at least 1 percent of patients and were more common than in the placebo group.
Like many immune-modulating medications, Sotyktu carries certain safety considerations.
Sotyktu may increase the risk of infections. Serious infections such as pneumonia and COVID-19 have been reported in clinical trials.
Patients should be monitored for symptoms of infection during treatment.
Herpes virus reactivation has been reported in studies. Screening for viral infections may be recommended before treatment.
Patients should be evaluated for tuberculosis prior to starting therapy. Those with latent TB may require preventive treatment.
Malignancies, including lymphomas, were observed in clinical trials. Healthcare providers should evaluate risks and benefits before prescribing the medication.
Doctors may monitor patients for:
Routine laboratory testing may be recommended during treatment.
Sotyktu was first approved by the FDA in 2022 for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Since that initial approval, several global regulatory agencies have authorized the medication for psoriasis treatment.
The new psoriatic arthritis approval expands the potential use of Sotyktu to another major inflammatory disease.
Psoriatic arthritis treatments have evolved significantly over the past decade, with biologic drugs and targeted therapies offering improved disease control.
However, many treatments require injections or infusions, which can be inconvenient for some patients.
Sotyktu provides a once-daily oral option that targets a specific immune pathway involved in the disease.
Potential benefits of this new therapy include:
For individuals who prefer oral medication or who do not respond well to existing therapies, this approval may expand treatment possibilities.
The development of TYK2 inhibitors is an area of active research in autoimmune diseases.
Researchers continue to investigate whether drugs like Sotyktu could be effective in other inflammatory conditions, including:
Long-term clinical studies and post-market data will help determine the full safety and effectiveness profile of the medication over time.
The FDA approval of Sotyktu (deucravacitinib) for adults with active psoriatic arthritis represents an important development in autoimmune disease treatment.
As the first TYK2 inhibitor approved for this condition, Sotyktu introduces a new mechanism of action that targets specific inflammatory pathways involved in both joint and skin symptoms.
Clinical trials demonstrated meaningful improvements in disease activity, physical functioning, and quality of life compared with placebo. While the medication carries potential risks and requires careful monitoring, it may provide a valuable treatment option for patients seeking an effective oral therapy.
As research continues and more real-world data emerge, healthcare providers will gain a clearer understanding of how Sotyktu fits into the broader treatment strategy for psoriatic arthritis.
This article is for informational and educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan. The information provided here is based on publicly available data and may not include all potential risks or updates related to the medication.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.